Supplementary Table 3. Severe adverse event or other adverse events led to the discontinuation of study drugs

No.	Arm	Strata: T-score	Age	Baseline 25(OH)D level	Adverse event	Serious	Severity	Causality	Action taken with study drug	Outcome
1	Raloxifene/vitamin D combination therapy group	≤-2.5	66	11.3	Nausea	No	Moderate	Possible	Discontinued	Recovered
2	Raloxifene/vitamin D combination therapy group	≤-2.5	63	32.1	Pelvic pain (left)	No	Moderate	Possible	Discontinued	Recovered
3	Raloxifene monotherapy group	≤-2.5	66	26.6	Oedema	No	Mild	Possible	Discontinued	Continuing
4	Raloxifene/vitamin D combination therapy group	>-2.5	64	30.7	Dyspepsia	No	Moderate	Possible	Discontinued temporarily	Recovered
5	Raloxifene/vitamin D combination therapy group	>-2.5	57	26.9	Spondylolisthesis	Yes	Severe	Unlikely	None	Recovered

25(OH)D, 25-hydroxy-vitamin D.

https://doi.org/10.11005/jbm.2022.29.3.155